Termination of Registration of a Class of Security Under Section 12(g) (15-12g)
06 March 2015 - 5:54AM
Edgar (US Regulatory)
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
OMB APPROVAL |
OMB Number: 3235-0167
Expires: March 31, 2015
Estimated average burden hours per response . . . . . 1.50 |
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number |
000-50156 |
|
Molecular Pharmacology (USA) Ltd. |
|
(Exact name of registrant as specified in its charter) |
|
284 Oxford Street, Leederville 6007, Perth, Western Australia |
|
(Address, including zip code, and telephone number, including area code, of
registrant's principal executive offices) |
|
Common Stock |
|
(Title of each class of securities covered by this Form) |
|
N/A |
|
(Titles of all other classes of securities for which a duty to file reports
under section 13(a) or 15(d) remains) |
|
|
|
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
Rule 12g-4(a)(1)
Rule 12g-4(a)(2)
Rule 12h-3(b)(1)(i)
Rule 12h-3(b)(1)(ii)
Rule 15d-6 |
■
□
□
□
□ |
|
|
|
|
Approximate number of holders of record as of the certification or notice
date: |
19 |
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of
registrant as specified in charter) has caused this certification/notice to
be signed on its behalf by the undersigned duly authorized person. |
|
|
|
Date: |
March 5, 2015 |
By: |
/s/ Jeffrey Edwards |
|
|
|
|
Jeffrey Edwards, Director |
|
|
|
Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the
General Rules and Regulations under the Securities Exchange Act of 1934. The
registrant shall file with the Commission three copies of Form 15, one of
which shall be manually signed. It may be signed by an officer of the
registrant, by counsel or by any other duly authorized person. The name and
title of the person signing the form shall be typed or printed under the
signature. |
|
|
|
|
|
|
|
|
|
|
Molecular Pharmacology (PK) (USOTC:MLPH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Molecular Pharmacology (PK) (USOTC:MLPH)
Historical Stock Chart
From Nov 2023 to Nov 2024
Real-Time news about Molecular Pharmacology Limited (PK) (OTCMarkets): 0 recent articles
More Molecular Pharmacology (usa) Ltd. News Articles